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In patients with symptoms suspicious of HIV-associated cryptococcal meningitis (CM), a positive 
serum CrAg is highly presumptive of culture confirmed CM and a positive cerebrospinal fluid CrAg is 
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Cryptococcal antigen (CrAg) detection could direct timely initiation of antifungal therapy. We 
searched MEDLINE and EMBASE for studies where CrAg detection in serum/cerebrospinal fluid (CSF) 
and CSF fungal culture were done on HIV-positive adults with suspected  cryptococcal meningitis 
(CM). With QUADAS-2, we evaluated risk of bias (RoB) of 11 included studies on 3,600 participants 
and used random-effects meta-analysis to obtain summary sensitivity and specificity of serum and 
CSF CrAg  as well as agreement between CSF CrAg and CSF culture. Summary sensitivity and 
specificity of serum CrAg was 99.8% (88.4 – 100) and 95.2% (88.7 – 98), respectively; of CSF CrAg was 
98.8% (96.2 – 99.6) and 99.3% (96.7 – 99.9), respectively. Agreement between CSF CrAg and CSF 
culture was 97% (96 – 99). In HIV-adults with CM symptoms, serum CrAg-negativity may rule out 
CM, positivity should prompt induction antifungal therapy if lumbar puncture is not feasible. In first 
episode of CM, CSF CrAg-positivity is diagnostic.   
Key words: Cryptococcus, antigen, diagnosis, latex agglutination, lateral flow assay 
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Cryptococcal meningitis (CM), a life-threatening systemic opportunistic fungal infection, occurs 
mainly in patients with defective cellular immunity [1, 2]. Consequent to acquired profound immune 
depression associated with the human immune deficiency virus (HIV) pandemic [3, 4], there has 
been a surge in the burden of CM, especially in low- and middle-income countries (LMIC) where 
more than 90% of CM is HIV-related [5]. In 2014, an estimated 223,100 cases of CM occurred, of 
which 181,100 were fatal, hence accounting for about 15% of all-cause HIV-associated mortality [6].  
The reference standard for diagnosing CM is the direct identification of the encapsulated yeast 
Cryptococcus spp. by microscopy of Indian ink-stained preparations of cerebrospinal fluid (CSF) or of 
yeast colonies cultured from CSF on Sabouraud’s dextrose agar [7, 8]. Consequently, confirmation of 
the diagnosis of CM requires specialised equipment, clinical and technical expertise, which are not 
always available in most LMICs. More so, patients’ acceptance of lumbar puncture (LP) in such 
settings is not guaranteed [9-12]. Therefore, poor outcome associated with delayed diagnosis 
emphasizes the need for alternative and reliable methods for timely diagnosis of CM [8].  
Cryptococcus spp. is characterised by the presence of a polysaccharide capsule containing 
cryptococcal antigen (CrAg) surrounding the cell wall. CrAg is shed into biological milieus during 
infection and constitutes a biomarker of cryptococcosis. Within the last half-century, growing 
interest in CrAg detection has resulted in the development of commercial CrAg tests, each based on 
antibody-antigen interactions, using latex agglutination (LA) assays, enzyme-linked immunosorbent 
assays (ELISA) [13, 14], or more recently, immunochromatographic lateral flow assays (LFA) [15, 16].  
In 2011, the United States Food and Drug Administration approved a point of care (POC) immunochromatographic CrAg LFA test [15]. CrAg 
LFA is affordable (about 2.5 USD per test) [17], detects all cryptococcal serotypes, has no constraints on reactant storage or technical 
expertise, and provides results within ten minutes [15, 16]. This POC CrAg test is currently recommended by WHO for routine systematic 
screening for cryptococcosis in the blood of asymptomatic HIV patients presenting with less than 100 CD4
+ cells/μL, before initiation of 
antiretroviral therapy (ART) [8].  
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without symptoms of central nervous system (CNS) disease revealed that up to a third of patients whose serum was CrAg positive had CM 
[11]. Such an evaluation in patients with symptoms suggestive of CNS disease could greatly improve the timeliness of clinical decision 
making and hence patient outcomes. This systematic review was designed to determine the diagnostic accuracy of CrAg 
detection in serum and CSF, as well as the prevalence of culture-confirmed CM in HIV-positive adults 
with symptoms suggestive of CM. 
METHODS  
This systematic review was registered at PROSPERO (www.crd.york.ac.uk/PROSPERO) as 
CRD42017069664, conducted according to Cochrane guidelines [18] and reported following the 
Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy 
Studies statement (Appendix 1) [19]. 
Eligibility criteria 
We included randomised trials, cross-sectional and cohort (prospective and retrospective) studies 
irrespective of country, region, continent, or level of care (primary, secondary, or tertiary). In these 
studies, CrAg detection had to be performed in blood or CSF of adults (age >18 years) with 
confirmed HIV serology, presenting with signs and symptoms suggestive of CM, using either LA, 
ELISA or LFA. In these patients, the reference standard for establishing the diagnosis of CM was 
direct yeast identification by microscopy of CSF or of colonies cultured from CSF and stained with 
India Ink, as defined by the European Organisation for Research and Treatment of Cancer/Invasive 
Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases 
Mycosis Study group (EORTC/MSG) Consensus Group [7]. Participants with a positive cryptococcal 
culture and/or Indian ink stain in CSF were considered as having proven CM; those with a negative 
cryptococcal culture and negative Indian ink stain were considered as not having CM. Studies 
published in English, French and Spanish were assessed for inclusion and those published in other 
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their high risk of bias (RoB) [20]. We included published and unpublished studies (e.g., conference 
abstracts). 
Search strategy and study selection 
A comprehensive search strategy was developed by a medical information specialist (R.S.) and 
adapted for MEDLINE (via PubMed) and EMBASE. Medical subject headings and other search words 
included: cryptococcal antigen, cryptococcal surface polysaccharide, cryptococcal meningitis, HIV, 
AIDS, LA, ELISA, and LFA (see search details  in Appendix 2). Searches were run from 1981 (year of 
first HIV case description) through September 17th, 2019. We did not use methodological filters, to 
avoid omitting relevant studies [21]. We also searched for included studies on Google Scholar for 
reports that cited these studies. Conference proceedings of the International Conference on 
Cryptococcus and Cryptococcosis (ICCC), Conference on Retroviruses and Opportunistic Infections 
(CROI), and International AIDS Society (IAS) were screened from 2010 onwards.  
During the study selection process, two review authors (E.T. and J.J.B.) independently screened 
citations for eligibility, first by perusing the title and abstracts. Studies irrelevant to the review 
question were excluded and the full text of relevant articles was retrieved for data extraction. 
Discrepancies were discussed and arbitrated by a third author (J.F.C.) to achieve consensus. 
Data extraction  
E.T. and J.J.B. independently extracted data from included studies into a previously piloted data 
collection form. Studies where more than one type of index test or the same index test on both 
serum and CSF had been evaluated were subdivided by index test and sample type into diagnostic 
cohorts (See Appendix 3 for detailed list). In this review, results of index tests and reference 
standards were considered as binary outcomes (positive or negative). Data on semi-quantitative 
CrAg titres or CSF fungal colony unit counts were not extracted because they were not relevant to 
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Information extracted from each study included study characteristics (first author, year of 
publication, design, setting), participant characteristics (number of participants, mean or median 
age, proportion of males, proportion of ART-naïve participants, mean or median CD4 counts, survival 
history), CrAg test characteristics (commercial name, test principle [LA, ELISA, or LFA], types of 
biological samples used (serum, CSF, or both), total number of samples tested, technical 
specifications for testing [heat inactivation, pronase pre-treatment, and dilutions prior to testing]), 
reference standard characteristics (commercial name, underlying principle, technical specifications, 
component tests if a composite reference standard was used), data from 2 x 2 contingency tables 
(number of true positives, false positives, true negatives, and false negatives, number of 
indeterminate results when reported), and any other information of relevance (e.g., funding source). 
Quality assessment 
RoB was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 
(QUADAS-2) tool [22]. This four-domain tool was adapted to suit the review question 
(Appendix 4). For each of the first three domains (patient selection, index test, and reference 
standard), the RoB as well as the applicability to the review question were evaluated and 
classified as either “low risk”, “high risk” or “unclear” (if insufficiently reported details). For 
the fourth domain (flow and timing), only RoB was evaluated.  
Statistical analysis and data synthesis  
The prevalence of serum and CSF CrAg positivity as well as of culture-confirmed CM among patients 
with symptoms suggestive of CNS disease was estimated by standard random-effects meta-analysis 
for proportions using the Freeman-Tukey double arcsine transformation [23]. Then, we fitted 
bivariate random-effects models to obtain summary estimates of sensitivity and specificity of CrAg in 
serum and CSF, and their 95% confidence intervals. When the bivariate model could not be fitted 
because the number of studies was small (less than four), univariate random-effects models were 
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presented by CrAg test (LA, ELISA, or LFA) and sample type (serum, CSF, or both). Random-effects 
meta-analysis was also used to obtain summary estimates of agreement between CSF CrAg and CSF 
culture in the study population, i.e., the proportion of tests that gave similar results between CSF 
CrAg and culture. Heterogeneity was evaluated by inspecting the forest plots and ROC space, and by 
calculating I2 statistics (when applicable). We performed meta-regression to investigate sources of 
heterogeneity across CrAg test (LA, ELISA, LFA) and sample types (serum vs. CSF), by incorporating 
covariates in the bivariate or univariate model as appropriate. We also performed sensitivity 
analyses using only studies judged as having “low” RoB. Statistical analysis involved use of Stata 16.0 
(Statacorp, Texas, USA). 
RESULTS  
Results of the search 
The electronic search performed on September 17th, 2019 identified 1972 citations (147 duplicates) 
of which 1794 were excluded based on title and abstract screening (Figure 1). Further assessment of 
31 citations resulted in the inclusion of 11 studies [14, 24-33]. Non-electronic searches did not 
identify any additional study.  
Study Characteristics  
Studies included for meta-analyses were published between 1990 and 2018 and conducted in 8 
countries (including 6 LMICs) on 3,600 adults living with HIV, clinically suspected of having CM (Table 
1). The median number of participants per study was 146 (IQR: 99 – 465), and they were 
predominantly male (71%). When reported, median age and CD4
+ count were 35.5 years and 27 
cells/µL, respectively.  
Across the 11 studies, the following commercial CrAg tests were evaluated: Pastorex (Sanofi 
Diagnostic Pasteur, France), Cryptococcal antigen latex agglutination system (CALAS, Meridian 
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agglutination (Crypto-LA, International Biological Labs, Cranberry, NJ, USA), Cryptococcal latex 
agglutination (Fumouze, France), CrAg LFA (IMMY Diagnostics, Oklahoma, USA), and StrongStep 
(Liming Bio, Nanjing, Jiangsu, China). Studies where more than one commercial CrAg tests were 
evaluated, were subdivided for data extraction for each test: three tests in two studies [14, 29] and 
two tests in one study [31]. These studies were further subdivided by sample type (serum or CSF) 
yielding a total of 24 diagnostic cohorts (8 on serum and 16 on CSF; Appendix 3).  
In terms of CrAg detection technologies, 7 of 11 (63.6%) studies evaluated LA (613 participants) [14, 
24, 25, 30-32], four (36.4%) evaluated LFA (2987 participants)  [26-29, 33], and none evaluated ELISA 
(Table 1). CrAg was assessed in both serum and CSF of the same participants in five studies (1846 
participants) [14, 25-28], only on serum, in one study (100 participants) [24], and only in CSF, in five 
studies (1654 participants) [29-33].  
In all 11 studies, CSF fungal culture was the reference standard for confirming CM. Five studies 
(45.5%) used both culture and direct microscopy of CSF (1259 participants) [24, 25, 29, 31, 32]. 
However, in four studies (1433 participants) [26, 28, 29, 31], a composite reference standard 
comprising culture, India Ink staining, CrAg tests, or polymerase chain reaction (PCR) was 
considered. No study relied solely on India Ink positivity as the reference standard. 
Methodological quality of included studies 
One study (9%) was deemed at high RoB with respect to the patient selection process [14], two 
(18.2%) studies on how the index test was performed [14, 33], four studies (36.4%) [26, 28, 29, 31] 
on the reference standard (because of composite reference standards), and one study (9%) [29] on 
the flow and timing of tests (Appendix 5). The four studies (36.4%) [26, 28, 29, 31] which used 
composite reference standards were also judged at high risk of applicability concerns (Appendix 6). 
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Prevalence of CrAg positivity and culture-confirmed CM  
The summary prevalence of serum CrAg in patients presenting with CNS symptoms was 63% (95% CI: 
45 – 81, I2 = 98.7%; Figure 2A). In CSF, the summary prevalence of CrAg was 37% (25 – 48, I2 = 99.2%; 
Figure 2B). Across studies, the prevalence of culture-confirmed CM ranged between 6% [33] and 
63% [29]. The summary prevalence of culture-confirmed CM was 43% (26 – 59, I2 = 99.2%; Figure 3). 
Diagnostic accuracy of CrAg  
In serum, across 8 diagnostic cohorts of 1946 participants [14, 24-28], the sensitivity of CrAg 
detection ranged from 83 to 100%, and specificity ranged from 72 to 100% (Figure 4A). Summary 
estimates of sensitivity and specificity of serum CrAg for detecting CM were 99.8% (88.4 – 99.9) and 
95.2% (88.8 – 98), respectively. 
In CSF, across 16 diagnostic cohorts of 3500 participants [25-33], the sensitivity of CrAg detection 
ranged from 80 to 100%, and specificity from 82 to 100% (Figure 4B). Summary estimates of 
sensitivity and specificity of CSF CrAg for detecting CM were 98.8% (96.2 – 99.6) and 99.3% (96.7 – 
99.8), respectively. In these 16 diagnostic cohorts (3500 participants) where CSF CrAg was compared 
with CSF culture, the summary agreement between CSF CrAg and CSF culture results was 97.0% (96 
– 99) (Table 2).  
Investigations of heterogeneity  
In serum, LA (5 diagnostic cohorts, 256 participants) summary sensitivity was 100% (99.5 – 100) and 
summary specificity was 96.7% (93.8 – 98.9); while for LFA (3 diagnostic cohorts, 1690 participants) 
the summary sensitivity was of 94.4% (83.1 – 99.9) at a specificity of 89.1% (73.5 – 98.4). LA showed 
higher sensitivity in serum than LFA (p = 0.04) but there was no statistically significant difference in 
specificity (p = 0.14); Table 3.   
In CSF, LA (10 diagnostic cohorts, 1810 participants) had a summary sensitivity of 97.1% (91.9 – 99.0) 
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summary sensitivity of 99.5% (97.2 – 99.9) and specificity of 99.5% (94.2 – 99.9). Though there was 
some weak statistical evidence that LFA may have better sensitivity in CSF (p = 0.07) than LA, their 
specificities were comparable (p = 0.54); Table 3.  
In 7 diagnostic cohorts comprising 1846 participants [14, 25-28], CrAg detection was performed in 
both serum and CSF in the same participants, which allowed a direct head-to-head comparison. 
There was no evidence that sensitivity and specificity differed between CrAg in serum and CrAg in 
CSF (sensitivity 99.7% (86.8 – 100) and 99.9% (97.1 – 100), respectively, p = 0.33; specificity 95.2% 
(87.7 – 98.2) and 99.5% (86 – 100), respectively, p = 0.77; Figure 5 and Appendix 7. 
Sensitivity analysis 
Sensitivity analysis using only studies judged to be of low RoB confirmed the robustness of results: in 
serum, CrAg sensitivity was 98.3% (90.3 – 100) and specificity was 93.8% (86.5 – 98.6) and in CSF, 
CrAg sensitivity was 99% (84 – 99.9) and specificity was 99.7 (91.9 – 100).  
DISCUSSION   
Main findings  
In this systematic review encompassing 11 studies (24 diagnostic cohorts, 3600 participants), we 
investigated the diagnostic accuracy of CrAg for detecting CM in HIV-infected adults presenting with 
CNS symptoms. We found that: (1) the prevalence of serum CrAg is about 60%, (2) the prevalence of 
culture-confirmed CM is about 40%, (3) the sensitivity and specificity of serum CrAg are 99% and 
95%, respectively (4) the sensitivity and specificity of CSF CrAg are 99% and 99%, respectively, (5) 
agreement between the results of CSF CrAg and CSF culture is 97%  
Implications for practice 
In routine practice, the utility of a medical test depends on its role in guiding clinical decisions that 
could impact patient outcomes. Tests used in CM, an extremely severe disease with a high fatality, 
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Concomittantly, the high cost of currently recommended induction treatment as well as potential 
amphotericin B (AmB)-related severe adverse events, not easy to monitor and manage in LMICs [36, 
37], requires these tests also to be highly specific.  
Among HIV-patients with CNS symptoms, we found that serum CrAg was highly predictive of 
confirmed CM [38] and was able to rule-out CM when negative. As such, in LMIC settings with a high 
burden of CM and no facilities for CSF analysis, systematically screening symptomatic patients for 
serum CrAg should become routine practice. If serum CrAg is positive, empirical inductive antifungal 
combination therapy should be started, unless the patient was previously known to have had 
cryptococcal infection. Thus, treatment is not delayed, although a lumbar puncture is still required in 
order to measure and manage CSF pressure; and provides the opportunity to confirm the diagnosis, 
and to confirm or not active infection in previously treated cases. Currently, systematic serum CrAg 
screening is recommended only for ART-naïve patients, prior to ART initiation [8]. However, with 
long term ART-interruption and therapy failure accounting for the majority of CM cases among ART-
experienced patients [39, 40], systematic serum CrAg in all CNS symptomatic HIV-patients is 
warranted. As such, among those with serum CrAg positivity and a negative CSF CrAg, other causes 
of CNS infection could be considered.  
Relying on India Ink staining of CSF and/or culture for confirmation of the diagnosis of CM requires a 
laboratory setting, trained technicians and sustainable reagents and equipment. Moreover, Indian 
Ink staining of CSF, which showed relatively low sensitivity in some studies, (as low as 86% [29, 41]), 
is only positive in the presence of a high fungal count and requires CSF centrifugation for highest 
sensitivity. Fungal culture, though reliable, requires viable organisms in CSF and laboratory 
incubation at 30˚C for several days to ensure fungal growth. This  is not always logistically feasible 
and may delay diagnosis and treatment. In this meta-analysis, a positive agreement between CSF 
CrAg and reference standard results was 97%. With such high accuracy, the increasing availability of 
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ability to analyse CSF, CSF CrAg is an alternative to conventional fungal culture, especially for first 
episodes of CM. 
Implications for research 
In CrAg-positive HIV-patients with asymptomatic underlying CM, a serum CrAg titre of at least 1:160 
is associated with culture-confirmed CM [9, 42]. Though we did not investigate serum CrAg titres in 
this review due to scarcity of data, its potential role as a biomarker of culture-confirmed CM in CNS 
symptomatic patients is of high clinical importance, warranting further evaluation.  
Limitations  
Our review had some limitations. The LFA assay, though very promising, was investigated in serum 
only in four studies, which may explain the apparent difference in sensitivity we found between LA 
and LFA in serum. Moreover, in some of the studies on CSF, diagnostic accuracy might have been 
over-estimated because of composite reference standards. Due to a low number of studies, we had 
to use univariate random-effects models to separately estimate the sensitivity and specificity of CrAg 
in serum as well as in the meta-regression analysis of sources of heterogeneity. Comparison of the 
performances of LA and LFA was indirect as only one study evaluated both tests in CSF, limiting our 
ability to draw firm conclusions.   
Conclusions  
On average, the accuracy of CrAg detection in serum and CSF of HIV-positive adults with signs and 
symptoms suggestive of CM is very high when compared with conventional fungal culture and 
microscopy following India Ink staining. In settings without facilities for CSF analysis or with low LP 
uptake, CrAg detection in serum may be sufficiently sensitive to rule-out CM, and sufficiently specific 
to start antifungal therapy in cases with a positive result. In settings where LP is feasible but where 
laboratory equipment is limited, CSF CrAg could replace culture and India Ink staining for 
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Figure legends:  
Figure 1: Flow diagram of the study selection process 
Figure 2. Prevalence of CrAg positivity in serum (2A) and CSF (2B) in HIV-positive adults with central 
nervous system symptoms 
Figure 3. Prevalence of confirmed cryptococcal meningitis (CM) in HIV-positive adults with central 
nervous system symptoms  
Figure 4. Forest plots of serum (8 cohorts) and CSF (16 cohorts) CrAg sensitivity and 
specificity for CM diagnosis in HIV-positive adults with central nervous system symptoms 
Figure 5. Direct head-to-head comparisons of serum and CSF CrAg performed in the same 
patients (7 cohorts). Circles and diamonds represent serum and CSF CrAg, respectively. The 
curved lines represent the summary ROC curves of sensitivity and specificity 
Appendix 5. Review authors’ judgment on risk of bias (RoB) and applicability concerns 
across all included studies (n=11) 
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Table 1. Characteristics of included studies (n = 11) 
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Table 2. Agreement between CSF CrAg and CSF culture results across diagnostic cohorts (n = 16) 
 
 CrAg test N No. CrAg (+) and 
culture (+) 
No. CrAg (-) and 
culture (+) 
No. CrAg (+) 
and culture (-) 
No. CrAg (-) and 
culture (-) 
Raw agreement between CSF CrAg 
and CSF culture results, % (95%CI) 
Nelson M.R. 1990 LA (IMMY) 69 16 0 0 53 100 (94.8 – 100) 
Temstet A. 1990 LA (Pastorex) 77 30 2 0 45 97.4 (90.1 – 99.7)  
LA (International biological) 41 30 0 2 9 95.1 (83.4 – 99.4)  
LA (Meridian) 41 30 0 2 9 95.1 (83.4 – 99.4)  
Boulware D.R. 2014 LFA (IMMY) 666 435 3 2 226 99.2 (98.3 – 99.8)  
LA (IMMY) 749 452 14 0 283 98.1 (96.9 – 99.0)  
LA (Meridian)  279 176 4 14 85 93.5 (90.0 – 96.1) 
Kabanda T. 2014 LFA (IMMY) 112 47 0 0 65 100 (96.8 – 100) 
LA (Meridian)  112 47 1 0 64 99.1 (95.1 – 100)  
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LA (Remel Inc.) 465 26 7 0 432 98.4 (96.9 – 99.4) 
Kammalac N.T. 2015 LA (Fumouze)  185 40 10 1 134 94.1 (89.6 – 97.0) 
Williams D.A. 2015 LFA (IMMY) 207 126 0 12 69 94.2 (90.1 – 97.0)  
Dharmshale S.N. 2016 LA (Meridian) 99 42 0 5 52 94.9 (88.6 – 98.3)  
Mpoza E. 2018 LFA (StrongStep)  142 101 0 0 41 100 (97.4 – 100)  
Ssebambulidde K. 2018 LFA (IMMY) 1201 671 3 0 527 99.8 (99.3 – 100)  
Random-effects meta-
analysis 
- 3500 - - - - 98.0% (97.0 – 99.0) 
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Table 3. Summary of diagnostic accuracy findings 
  Quantity of evidence Summary estimates 




LA 5 256 100 (99.5-100)* 96.7 (93.8-98.9)* 
LFA 3 1690 94.4 (83.1-99.9)* 89.1 (73.5-98.4)* 
Overall serum 
CrAg 
8 1946 99.8 (88.4- 99.9)** 95.2 (88.8-98.0)** 
p-value*** 8 - 0.04 0.14 
CSF 
 
LA 10 1810 97.1 (91.9-99.0)** 99.1 (93.8-99.9)** 
LFA 6 3099 99.5 (97.2-99.9)** 99.5 (94.2-100)** 
Overall CSF CrAg 16 3500 98.8 (96.2-99.6)** 99.3 (96.7-99.9)** 
p-value*** 16 - 0.07 0.54 
Abbreviations: CrAg, cryptococcal antigen; LA, latex agglutination; LFA, lateral flow assay; CSF, cerebrospinal 
fluid; CI, confidence interval 
*univariate random-effects model; **bivariate random-effects model; ***univariate logit-normal random-
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